Slamon DJ, Neven P, Chia S, et al. - Given that progression-free survival with ribociclib plus fulvestrant vs fulvestrant alone was greater in postmenopausal patients with hormone-receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer studied in an earlier analysis of this phase 3 trial, researchers describe the outcomes of a protocol-specified second interim analysis of overall survival in this study. In a random manner (2:1 ratio), patients were given either ribociclib or placebo in addition to fulvestrant as first-line or second-line treatment. In the ribociclib group and in the placebo group, the overall survival at 42 months was estimated to be 57.8% and 45.9%, respectively. Findings revealed a significant overall survival benefit of ribociclib plus fulvestrant over placebo plus fulvestrant in patients with hormone-receptor–positive, HER2-negative advanced breast cancer.